Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients

Summary

The study will be a non-randomized, open label, single dose, single blind, placebo control, single center, single arm study in Type I diabetes patients. The study will include single dose administration for the evaluation of single dose acute toxicity, pharmacokinetics and activity.

Timeline

Start

2010-10

Primary completion

2011-02

Completion

2011-02

Drugs

Indications